HK Stock Market Move | WUXI BIO (02269) up by over 3%. The company has reached a research service cooperation agreement with DuoXin Biotechnology and Aadi on three innovative ADCs.
WuXi Biologics (02269) rose more than 3%, up 2.94% as of the time of writing, at HK$17.52, with a turnover of HK$261 million.
WUXI BIO (02269) rose more than 3%, rallying 2.94% as of press time, to 17.52 Hong Kong dollars, with a turnover of 261 million Hong Kong dollars.
On the news front, on December 20th, WUXI BIO announced a research service cooperation agreement with Hangzhou Dual-Dixy Biological Technology Co., Ltd. and Aadi Bioscience to support Aadi in the development of three next-generation antibody-drug conjugates (ADCs) in pre-clinical stage. Under the terms of the agreement, Aadi will pay WUXI BIO and Dual-Dixy Biological a first payment of 44 million US dollars, up to 265 million US dollars in development milestone payments, 540 million US dollars in commercial milestone payments, and a single-digit percentage of sales royalties.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
